Research Output Journal of Engineering and Scientific Research 4(3): 39-42, 2025

ROJESR Publications

Online ISSN: 1115-9790

https://rojournals.org/roj-engineering-and-scientific-research/

Print ISSN: 1115-6155

https://doi.org/10.59298/ROJESR/2025/4.3.3942

Mitochondrial Transfer from Mesenchymal Stem Cells to Diabetic Cardiomyocytes: A Novel Strategy to Mitigate Diabetic Cardiomyopathy

Obwendo N. J.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Diabetic cardiomyopathy (DCM) is a major complication of diabetes mellitus, characterized by mitochondrial dysfunction, oxidative stress, and impaired cardiac contractility. Conventional therapies fail to address the underlying bioenergetic deficits, necessitating novel strategies such as mitochondrial transfer from mesenchymal stem cells (MSCs) to damaged cardiomyocytes. This review critically evaluated the mechanisms by which MSCs donate healthy mitochondria via tunneling nanotubes (TNTs), extracellular vesicles, or cell fusion, thereby restoring ATP production, reducing oxidative stress, and enhancing cardiomyocyte survival in DCM. Preclinical studies in rodent models and *in vitro* systems demonstrate that MSC-mediated mitochondrial transfer improves cardiac function, mitigates fibrosis, and rescues bioenergetic failure. However, challenges such as transfer efficiency, immunogenicity, and delivery optimization must be addressed before clinical translation. Emerging technologies, including mitochondrial nanocarriers and engineered MSCs, offer promising solutions. By synthesizing current evidence, this review highlights the therapeutic potential of mitochondrial transfer while outlining key research directions for future investigation. This article was developed through a comprehensive analysis of peer-reviewed preclinical studies, mechanistic insights, and emerging therapeutic strategies in mitochondrial medicine. If successfully translated, MSC-derived mitochondrial transfer could revolutionize DCM treatment by targeting its root cause rather than just symptoms.

Keywords: Mitochondrial transfer, Mesenchymal stem cells (MSCs), Diabetic cardiomyopathy (DCM), Mitochondrial dysfunction, Cardioprotection.

INTRODUCTION

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes mellitus, characterized by structural and functional abnormalities in the heart independent of coronary artery disease or hypertension [1, 2]. The pathophysiology of DCM involves metabolic disturbances, oxidative stress, inflammation, and mitochondrial dysfunction, which collectively contribute to impaired cardiac contractility and eventual heart failure. Among these factors, mitochondrial dysfunction is a central player, as cardiomyocytes are highly dependent on mitochondrial ATP production to sustain their continuous mechanical activity. In diabetic states, persistent hyperglycemia and lipid overload lead to excessive reactive oxygen species (ROS) production, mitochondrial DNA (mtDNA) damage, and impaired bioenergetics, further exacerbating cardiac dysfunction [3, 4].

Conventional therapeutic approaches for DCM primarily target glycemic control and symptom management but fail to address the underlying mitochondrial pathology [5, 6]. This therapeutic gap has spurred interest in novel strategies aimed at restoring mitochondrial function in diabetic cardiomyocytes. One emerging approach is mitochondrial transfer from mesenchymal stem cells (MSCs) to damaged cells. MSCs possess a unique ability to donate healthy mitochondria to stressed cells via tunneling nanotubes (TNTs), extracellular vesicles, or cell fusion [7]. This intercellular mitochondrial transfer has been shown to rescue bioenergetic deficits, reduce oxidative stress, and improve cell survival in various disease models, including ischemic heart injury and neurodegenerative disorders.

Given the pivotal role of mitochondrial dysfunction in DCM, MSC-mediated mitochondrial transfer presents a promising therapeutic avenue. This review explores the mechanisms underlying mitochondrial transfer, the evidence supporting its cardioprotective effects in diabetic cardiomyopathy, and the challenges that must be addressed before clinical translation. By critically evaluating preclinical studies and emerging technologies, we highlight the potential of this strategy to revolutionize the treatment of DCM.

Pathophysiology of Diabetic Cardiomyopathy and Mitochondrial Dysfunction

Diabetic cardiomyopathy develops because of chronic metabolic disturbances, including hyperglycemia, hyperlipidemia, and insulin resistance [8, 9]. These conditions disrupt cardiac energy metabolism, leading to an overreliance on fatty acid oxidation, which increases ROS production and impairs mitochondrial efficiency. Key features of mitochondrial dysfunction in DCM include:

i. **Reduced Oxidative Phosphorylation (OXPHOS):** Impaired electron transport chain (ETC) activity decreases ATP synthesis, compromising cardiomyocyte contractility.
ii. **Mitochondrial ROS Overproduction:** Excessive ROS damages lipids, proteins, and mtDNA, further impairing mitochondrial function [10].
iii. **Mitochondrial Dynamics Disruption:** Altered fission and fusion dynamics lead to fragmented mitochondria with reduced bioenergetic capacity [11].
iv. **Impaired Calcium Handling:** Mitochondrial calcium overload exacerbates oxidative stress and triggers apoptosis.

These abnormalities collectively contribute to cardiomyocyte death, fibrosis, and diastolic dysfunction, hallmark features of DCM. Restoring mitochondrial health is thus a logical therapeutic target.

Mesenchymal Stem Cells as Mitochondrial Donors

MSCs are multipotent stromal cells with regenerative properties, largely attributed to their paracrine signaling and direct cell-to-cell interactions [12]. Recent studies highlight their ability to transfer mitochondria to injured cells, a process mediated by:

i. **Tunneling Nanotubes (TNTs):** Thin, actin-based membrane bridges that facilitate organelle transfer between cells.
ii. **Extracellular Vesicles (EVs):** Exosomes and microvesicles containing mitochondrial components or whole mitochondria [13].
iii. **Cell Fusion:** Direct merging of MSC and recipient cell membranes, allowing organelle exchange [14].

MSC-derived mitochondrial transfer has been shown to rescue aerobic respiration, reduce oxidative damage, and enhance cell survival in various injury models. In the context of DCM, preclinical studies suggest that MSCs can replenish dysfunctional cardiomyocyte mitochondria, improving cardiac function.

Mechanisms of Mitochondrial Transfer in Diabetic Cardiomyopathy

Several mechanisms underline the therapeutic benefits of MSC-mediated mitochondrial transfer in DCM:

i. **Bioenergetic Restoration:** Transferred mitochondria into recipient cardiomyocytes, replenishing ETC components and restoring ATP production [15]. This is particularly crucial in diabetic hearts, where energy deficiency exacerbates contractile dysfunction.
ii. **Oxidative Stress Mitigation:** Healthy mitochondria from MSCs reduce ROS overproduction by improving electron flow efficiency and enhancing antioxidant defenses (e.g., superoxide dismutase) [16].
iii. **Anti-Apoptotic Effects:** By stabilizing mitochondrial membrane potential and preventing cytochrome c release, transferred mitochondria inhibit cardiomyocyte apoptosis.
iv. **Improved Calcium Homeostasis:** Functional mitochondria enhance calcium buffering, reducing diastolic dysfunction and arrhythmia risk [17].

Preclinical Evidence Supporting Mitochondrial Transfer Therapy

Animal studies have demonstrated the efficacy of MSC-mediated mitochondrial transfer in DCM:

i. **Rodent Models:** Diabetic mice receiving MSC co-culture or mitochondrial injection showed improved cardiac output, reduced fibrosis, and enhanced mitochondrial respiration [18].
ii. **In Vitro Studies:** High-glucose-treated cardiomyocytes co-cultured with MSCs exhibited restored ATP levels and reduced apoptosis [19].

These findings suggest that mitochondrial transfer could be a viable therapeutic strategy, though challenges remain in optimizing delivery methods and ensuring long-term engraftment.

Challenges and Future Directions

Despite promising preclinical results, several hurdles must be addressed:

i. **Efficiency of Transfer:** Only a fraction of cardiomyocytes receives mitochondria; strategies to enhance uptake are needed.

ii. **Immunogenicity:** Allogeneic MSCs may trigger immune responses; autologous or engineered MSCs could mitigate this [20].
iii. **Delivery Methods:** Systemic infusion may lead to off-target effects; localized cardiac delivery approaches are under investigation.
iv. **Long-Term Safety:** The risk of tumorigenesis or arrhythmias due to mitochondrial heteroplasmy requires further study [21].

Emerging technologies, such as mitochondrial nanocarriers and genetically modified MSCs, may overcome these limitations.

CONCLUSION

Mitochondrial transfer from MSCs to diabetic cardiomyocytes represents a groundbreaking therapeutic strategy for diabetic cardiomyopathy, addressing the root cause of bioenergetic failure rather than merely alleviating symptoms. Preclinical studies demonstrate that healthy mitochondria from MSCs can restore ATP production, reduce oxidative damage, and improve cardiac function in diabetic models. However, key challenges such as transfer efficiency, delivery optimization, and long-term safety must be resolved before clinical application. Future research should focus on enhancing mitochondrial uptake, developing targeted delivery systems, and conducting large-scale animal studies to validate efficacy and safety. If successful, this approach could revolutionize DCM treatment, offering a regenerative solution beyond conventional pharmacotherapy. By bridging the gap between stem cell biology and mitochondrial medicine, MSC-mediated mitochondrial transfer holds immense promise for mitigating diabetic cardiomyopathy and improving patient outcomes.

REFERENCES

1. Hu, X., Bai, T., Xu, Z., Liu, Q., Zheng, Y., Cai, L.: Pathophysiological Fundamentals of Diabetic Cardiomyopathy. Compr Physiol. 7, 693–711 (2017). https://doi.org/10.1002/J.2040-4603.2017.TB00752.X
2. Murtaza, G., Virk, H.U.H., Khalid, M., Lavie, C.J., Ventura, H., Mukherjee, D., Ramu, V., Bhogal, S., Kumar, G., Shanmugasundaram, M., Paul, T.K.: Diabetic cardiomyopathy - A comprehensive updated review. Prog Cardiovasc Dis. 62, 315–326 (2019). https://doi.org/10.1016/J.PCAD.2019.03.003
3. Cojocaru, K.A., Luchian, I., Goriuc, A., Antoci, L.M., Ciobanu, C.G., Popescu, R., Vlad, C.E., Blaj, M., Foia, L.G.: Mitochondrial Dysfunction, Oxidative Stress, and Therapeutic Strategies in Diabetes, Obesity, and cardiovascular disease. Antioxidants 2023, Vol. 12, Page 658. 12, 658 (2023). https://doi.org/10.3390/ANTIOX12030658
4. Teodoro, J.S., Nunes, S., Rolo, A.P., Reis, F., Palmeira, C.M.: Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes. Front Physiol. 10, 387172 (2019). https://doi.org/10.3389/FPHYS.2018.01857/XML/NLM
5. Cai, C., Wu, F., He, J., Zhang, Y., Shi, N., Peng, X., Ou, Q., Li, Z., Jiang, X., Zhong, J., Tan, Y.: Mitochondrial quality control in diabetic cardiomyopathy: from molecular mechanisms to therapeutic strategies. Int J Biol Sci. 18, 5276 (2022). https://doi.org/10.7150/IJBS.75402
6. Huo, J.L., Feng, Q., Pan, S., Fu, W.J., Liu, Z., Liu, Z.: Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discovery 2023 9:1. 9, 1–9 (2023). https://doi.org/10.1038/s41420-023-01553-4
7. Rajan, T.S., Gugliandolo, A., Bramanti, P., Mazzon, E.: Tunneling Nanotubes-Mediated Protection of Mesenchymal Stem Cells: An Update from Preclinical Studies. International Journal of Molecular Sciences 2020, Vol. 21, Page 3481. 21, 3481 (2020). https://doi.org/10.3390/IJMS21103481
8. Nakamura, M., Sadoshima, J.: Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 598, 2977–2993 (2020). https://doi.org/10.1113/JP276747
9. Jia, G., DeMarco, V.G., Sowers, J.R.: Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nature Reviews Endocrinology 2015 12:3. 12, 144–153 (2015). https://doi.org/10.1038/nrendo.2015.216
10. Cui, H., Kong, Y., Zhang, H.: Oxidative Stress, Mitochondrial Dysfunction, and Aging. J Signal Transduct. 2012, 646354 (2012). https://doi.org/10.1155/2012/646354
11. Ren, L., Chen, X., Chen, X., Li, J., Cheng, B., Xia, J.: Mitochondrial Dynamics: Fission and Fusion in Fate Determination of Mesenchymal Stem Cells. Front Cell Dev Biol. 8, 580070 (2020). https://doi.org/10.3389/FCELL.2020.580070/XML/NLM
12. Andreeva, E., Bobyleva, P., Gornostaeva, A., Buravkova, L.: Interaction of multipotent mesenchymal stromal and immune cells: Bidirectional effects. Cytotherapy. 19, 1152–1166 (2017). https://doi.org/10.1016/J.JCYT.2017.07.001
13. Liu, D., Dong, Z., Wang, J., Tao, Y., Sun, X., Yao, X.: The existence and function of mitochondrial component in extracellular vesicles. Mitochondrion. 54, 122–127 (2020). https://doi.org/10.1016/J.MITO.2020.08.005

14. Iorio, R., Petricca, S., Mattei, V., Delle Monache, S.: Horizontal mitochondrial transfer as a novel bioenergetic tool for mesenchymal stromal/stem cells: molecular mechanisms and therapeutic potential in a variety of diseases. Journal of Translational Medicine 2024 22:1. 22, 1–17 (2024). https://doi.org/10.1186/S12967-024-05047-4
15. Pour, P.A., Hosseinian, S., Kheradvar, A.: Mitochondrial transplantation in cardiomyocytes: Foundation, methods, and outcomes. Am J Physiol Cell Physiol. 321, C489–C503 (2021). https://doi.org/10.1152/AJPCELL.00152.2021/ASSET/IMAGES/LARGE/AJPCELL.00152.2021_F007.JPEG
16. Panahi, M., Rahimi, B., Rahimi, G., Yew Low, T., Saraygord-Afshari, N., Alizadeh, E.: Cytoprotective effects of antioxidant supplementation on mesenchymal stem cell therapy. J Cell Physiol. 235, 6462–6495 (2020). https://doi.org/10.1002/JCP.29660
17. Ramaccini, D., Montoya-Uribe, V., Aan, F.J., Modesti, L., Potes, Y., Wieckowski, M.R., Krga, I., Glibetić, M., Pinton, P., Giorgi, C., Matter, M.L.: Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy. Front Cell Dev Biol. 8, 624216 (2021). https://doi.org/10.3389/FCELL.2020.624216/XML/NLM
18. Mukkala, A.N., Jerkic, M., Khan, Z., Szaszi, K., Kapus, A., Rotstein, O.: Therapeutic Effects of Mesenchymal Stromal Cells Require Mitochondrial Transfer and Quality Control. International Journal of Molecular Sciences 2023, Vol. 24, Page 15788. 24, 15788 (2023). https://doi.org/10.3390/IJMS242115788
19. Pethe, P., Kale, V.: Placenta: A gold mine for translational research and regenerative medicine. Reprod Biol. 21, 100508 (2021). https://doi.org/10.1016/J.REPBIO.2021.100508
20. English, K., Mahon, B.P.: Allogeneic mesenchymal stem cells: Agents of immune modulation. J Cell Biochem. 112, 1963–1968 (2011). https://doi.org/10.1002/JCB.23119
21. Pérez-Amado, C.J., Bazan-Cordoba, A., Hidalgo-Miranda, A., Jiménez-Morales, S.: Mitochondrial Heteroplasmy Shifting as a Potential Biomarker of Cancer Progression. International Journal of Molecular Sciences 2021, Vol. 22, Page 7369. 22, 7369 (2021). https://doi.org/10.3390/IJMS22147369

CITE AS: Obwendo N. J. (2025). Mitochondrial Transfer from Mesenchymal Stem Cells to Diabetic Cardiomyocytes: A Novel Strategy to Mitigate Diabetic Cardiomyopathy. Research Output Journal of Engineering and Scientific Research 4(3): 39-42. https://doi.org/10.59298/ROJESR/2025/4.3.3942